MedPath

HILLMED INC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Early Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (100.0%)

A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management

Early Phase 1
Not yet recruiting
Conditions
Chronic Pain
Interstitial Cystitis
Pelvic Floor; Relaxation
Pelvic Floor Disorders
Interventions
Device: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device
Drug: Botulinum Neurotoxin
First Posted Date
2021-09-30
Last Posted Date
2023-09-21
Lead Sponsor
HillMed Inc.
Target Recruit Count
46
Registration Number
NCT05062902
Locations
🇺🇸

Baylor College of Medicine, Houston, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.